Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis

Xiaohui Wang1,2,*, Zhengqiang Bao1,2,*, Xiaoju Zhang3,*, Fei Li1, Tianwen Lai1, Chao Cao1, Zihhua Chen1, Wen Li1, Huahao Shen1,4 and Songmin Ying1,2

1 Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, China
2 Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, China
3 Department of Respiratory Medicine, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
4 State Key Laboratory of Respiratory Diseases, Guangzhou, China
* These authors have contributed equally to this manuscript

Correspondence to: Songmin Ying, email: yings@zju.edu.cn
Correspondence to: Huahao Shen, email: huahaoshen@zju.edu.cn

Keywords: PD-1, PD-L1, nivolumab, pembrolizumab, cancer

ABSTRACT

Background: PD-1/PD-L1 inhibitors have been implicated as potentially effective anti-cancer therapies. Some clinical randomized controlled trials (RCTs) have been completed for a variety of PD-1/PD-L1 inhibitors to treat various malignancies, and more RCTs are still under way. We carried out this systematic meta-analysis to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors.

Methods: We searched PubMed, EMBASE, clinical trial registers, conference reports, and related reviews. Eligible RCTs that compared PD-1/PD-L1 inhibitors with other chemotherapy agents or placebo in solid tumor patients were included. For each RCT, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), stable disease rate (SDR), progressive disease rate (PDR), and adverse events (AEs) were pooled for meta-analysis.

Findings: Based on an analysis of 10 eligible RCTs, PD-1/PD-L1 inhibitors were found to significantly improve PFS (Hazard ratio (HR), 0.65; 95% confidence interval (CI) 0.53 to 0.79, \(P<0.001\)), OS (HR, 0.69; 95%CI 0.62 to 0.76, \(P<0.001\)), and ORR (Risk Ratio (RR) 2.92; 95% confidence interval (CI) 2.06 to 4.15, \(P<0.00001\)) in all populations, including melanoma and NSCLC subgroups. However, they failed to increase the DCR of cancer patients (RR 1.15; 95%CI 0.91 to 1.45, \(P=0.25\)). Furthermore, less AEs were observed in the PD-1/PD-L1 inhibitor groups than the control groups.

Interpretation: PD-1 inhibitors are more effective for improving the PFS, OS, and ORR of cancer patients with little toxicity, despite having little effect on increasing of the DCR.

INTRODUCTION

Escape from immune surveillance is an important characteristic of carcinoma [1]. The development of therapies to enhance tumor immunity has become an important target for cancer treatment strategies [2]. Immune checkpoint inhibitors have achieved remarkable progress in tumor treatment, and two vital checkpoint
receptors, CTLA-4 and the programmed death-1 receptor (PD-1), have been studied most extensively in clinical cancer immunotherapy [3, 4]. These receptors play significant roles in regulating the immune response against malignancy.

The CTLA-4 blocking antibody ipilimumab [3] has entered clinical trials for the treatment of different human cancers. PD-1 blocking antibodies have also been studied extensively. PD-1 is a cell surface receptor that belongs to the CD28 immunoglobulin superfamily, which is usually expressed on activated T cells, Tregs, activated B cells, NK cells, and monocytes [4, 5]. PD-1 is an immune checkpoint that plays a significant role in down-regulating the immune system by limiting the activity of T-cells in the periphery during an inflammatory response [6]. The checkpoint receptor PD-1 interacts with its ligands PD-L1 and PD-L2 to inhibit T cell activation and proliferation, thereby promoting immunological self-tolerance [7, 8].

Tumor cells often use the PD-1-PD-L1/2 pathway to evade immune-cell attack [9]. Blockade of this pathway was shown to restore and improve antitumor immune response. In cancer patients, PD-1 is usually highly expressed on T cells and causes tumor-related immune suppression [10]. It has recently emerged as an effective therapeutic option for various cancers, with anti-PD-1 or anti-PD-L1 antibodies showing broad-ranging anti-tumor activity in early-phase trials [11-13].

Notably, the anti-PD-1 antibodies pembrolizumab and nivolumab were approved by the US FDA for the treatment of patients who were previously treated for metastatic melanoma [14]. Nivolumab is a monoclonal antibody against PD-1 [15] and has been tested in trials for the treatment of melanoma, non-small cell lung cancer (NSCLC) [16], ovarian cancer, and renal cell carcinoma [17]. Pembrolizumab is a monoclonal antibody that blocks the interaction of PD-1 on T cells with its ligands [18], which is suggested for antitumor activity in patients with advanced NSCLC or advanced melanoma. In addition, a series of phase I/II trials using pembrolizumab on other types of cancer is currently being investigated. Other anti-PD-1 antibodies and anti-PD-L1 antibodies are also being tested in different clinical trials, such as pidizumab [19], MPDL3280A [20], and BMS-936559 [12].

Recent studies have shown that anti-PD-1 and anti-PD-L1 monoclonal antibodies play positive roles in the development of cancer treatment. So far, a number of phase 2 or 3 studies have been completed on PD-1 blockade for different tumor treatments, and clinical trials for PD-L1 inhibitors are still in progress. Thus, we performed a meta-analysis that incorporates all available results to evaluate the efficacy and safety of PD-1 inhibition therapy.

**RESULTS**

Our search strategy originally retrieved 8676 records. Among these, 7887 articles were excluded for not being RCTs, and 798 articles were excluded by screening the title and abstract. After carefully reading the full texts of the remaining 71 articles, 10 eligible studies [21-30] met the inclusion criteria, as shown in Figure 1. Finally, a total of 5246 patients were enrolled. The median age of the patients was similar and ranged from 59 to 66 years. The 10 included studies were all published between 2014 and 2019.

![Figure 1: The process of literature search and eligible trials selection.](image)
Of the 10 included studies, 7 studies used the PD-1 inhibitor nivolumab, 2 studies used the PD-1 inhibitor pembrolizumab, and 1 study investigated the PD-L1 inhibitor atezolizumab. There were 6 studies about melanoma, 3 studies were related to NSCLC treatment, and 1 study was on renal-cell carcinoma. The detailed characteristics of the 10 studies are presented in Table 1.

Table 1: Characteristics of the trials included in the meta-analysis

| Research orientation | Phase | Cancer type | Treatment | Median PFS (months) | Female/Patients(No.) | Age in years, Median(range) | PD-L1 positive/negative | BRAF mutation/wild-type |
|----------------------|-------|-------------|-----------|---------------------|----------------------|---------------------------|------------------------|-------------------------|
| Weber J.S 2015       | III   | melanoma    | Nivolumab 3mg/kg every 2 weeks | 4.7 | 96(272) | 59(23-88) | 134/138 | 60/212 |
|                      |       |             | Chemotherapy | 4.2 | 48(133) | 62(29-85) | 29/66 | 29/104 |
| Larkin J 2015        | III   | melanoma    | Nivolumab 3mg/kg every 2 weeks | 6.9 | 114(316) | 59(25-90) | 80/208 | 100/316 |
|                      |       |             | Nivolumab 1mg/kg every 3 weeks + Ipilimumab 3mg/kg every 2 weeks | 11.5 | 108(314) | 59(18-88) | 68/210 | 101/213 |
|                      |       |             | Ipilimumab | 2.9 | 113(315) | 61(18-89) | 75/202 | 97/218 |
| Larkin J 2015        | III   | melanoma    | Pembrolizumab 3mg/kg every 2 weeks | 5.5 | 118(279) | 61(18-89) | 225/54 | 98/181 |
|                      |       |             | Pembrolizumab 3mg/kg every 3 weeks | 4.1 | 103(277) | 63(22-89) | 221/56 | 97/180 |
|                      |       |             | Ipilimumab | 2.8 | 116(278) | 62(18-88) | 225/53 | 107/171 |
| Brahmer J 2015       | III   | NSCLC       | Nivolumab 3mg/kg every 2 weeks | 3.5 | 24(135) | 62(39-85) | NA | NA |
|                      |       |             | Pembrolizumab 10mg/kg every 3 weeks | 5.8 | 72(181) | 60(27-89) | NA | 40/141 |
|                      |       |             | Docetaxel | 2.8 | 49(137) | 64(42-84) | NA | NA |
| Robert C 2015        | III   | melanoma    | Nivolumab 3mg/kg every 2 weeks | 5.1 | 89(210) | 64(18-86) | 74/136 | 0/202 |
|                      |       |             | Dacarbazine | 2.2 | 83(208) | 66(26-87) | 74/134 | 0/204 |
| Ribas A 2015         | II    | melanoma    | Pembrolizumab 2mg/kg every 2 weeks | 5.4 | 76(180) | 62(15-87) | NA | 44/136 |
|                      |       |             | Pembrolizumab 10mg/kg every 3 weeks | 5.8 | 72(181) | 60(27-89) | NA | 40/141 |
|                      |       |             | Chemotherapy | 3.6 | 65(179) | 63(27-87) | NA | 41/138 |
| Postow MA 2015       | I     | melanoma    | Nivolumab 1mg/kg every 3 weeks + Ipilimumab 3mg/kg every 2 weeks | NA | 32(95) | 64(27-87) | NA | 23/72 |
|                      |       |             | Ipilimumab | 4.4 | 15(47) | 67(31-80) | NA | 10/37 |
| Borghaei H 2015      | III   | NSCLC       | Nivolumab 3mg/kg every 2 weeks | 2.3 | 141(292) | 61(37-84) | NA | NA |
|                      |       |             | Docetaxel | 4.2 | 122(290) | 64(21-85) | NA | NA |
| Motzer R.J 2015      | III   | Renal-cell Carcinoma | Nivolumab 3mg/kg every 2 weeks | 4.6 | 95(410) | 107(411) | NA | NA |
|                      |       |             | Everolimus | 4.4 | 62(411) | 62(18-86) | NA | NA |
| Fehrenbacher L 2016  | II    | NSCLC       | Atezolizumab 1200mg/m² every 3 weeks | 2.7 | 51(144) | 62(42-82) | 96/48 | NA |
|                      |       |             | Docetaxel | 3 | 67(143) | 61(36-84) | 82/61 | NA |

NSCLC: Non-Small-Cell Lung Cancer; NA: not available; PFS: Progression-free survival

2016. Of the 10 included studies, 7 studies used the PD-1 inhibitor nivolumab, 2 studies used the PD-1 inhibitor pembrolizumab, and 1 study investigated the PD-L1 inhibitor atezolizumab. There were 6 studies about melanoma, 3 studies were related to NSCLC treatment, and 1 study was on renal-cell carcinoma. The detailed characteristics of the 10 studies are presented in Table 1.

Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), stable disease rate (SDR), and progressive disease rate (PDR) of all populations

PFS, OS, ORR, DCR, SDR and PDR are the important end points of tumor RCTs. Progressive-free survival (PFS) is a measure of the activity of a treatment
on tumors. It is the time that passes from a certain date (generally the first day of treatment, or the day in which a patient is enrolled in a clinical trial) and the date on which disease “progresses” or the date on which the patient dies, from any cause. Overall survival (OS) is a primary end point usually, Patients with tumors can die directly from that disease or from an unrelated cause. When the precise cause of death is not specified, this is called the overall survival rate or observed survival rate. Researchers often use mean overall survival rates to estimate the patient’s prognosis. Objective response rate (ORR) is another important end point of clinical cancer research, Objective Response Rate is the percentage of patients whose cancer shrinks or disappears after treatment. Which often used as a clinical endpoint for clinical trials of cancer treatments. Disease Control Rate (DCR) is the sum of complete response rate, partial response rate and stable disease rate. Progressive Disease Rate (PDR) is the percentage of patients whose cancer progress.

There were 9 trials that reported the ORR and DCR of the overall population among the 10 studies included. The ORR was also significantly higher in the PD-1 inhibitor treatment groups (715/2035, 35%) than the control groups (210/1812, 11%), with an RR of 2.92 (95% CI 2.06 to 4.15, P < 0.00001) (Figure 3A). Although the PD-1 inhibitor showed a slight trend of improving the DCR when compared with control arms, the result was not significant with an RR of 1.15 (95% CI 0.91 to1.45, P = 0.25) (Figure 3B).

It was apparent that PD-1 inhibitors were more effective in improving the ORR of cancer patients. However, significantly more patients in the control arms reached stable disease status (RR 0.58; 95% CI 0.45 to 0.75; P < 0.0001) (Figure 4A). Although the difference was not significant, PD-1 inhibitors had a slight trend of decreasing the PDR compared with the control arms (RR 0.76; 95% CI 0.53 to 1.09; P = 0.13) (Figure 4B).

**Objective response rate (ORR) and disease control rate (DCR) of melanoma and NSCLC subgroups**

As mentioned, 6 studies were related to melanoma and 2 studies were related to lung cancer. Thus, we carried out subgroup analyses to explore the efficiency of PD-1 inhibitors in the treatment of melanoma and lung cancer. The results show that PD-1 inhibitors could increase the ORR of melanoma patients compared with the control groups (RR 2.89; 95% CI 2.02 to 4.13; P < 0.00001) (Figure 3A). PD-1 inhibitors could also significantly increase the ORR of patients in the NSCLC populations (RR 1.72; 95% CI 1.22 to 2.43; P = 0.002) (Figure 3A). However, PD-1 inhibitors failed to increase the DCR of patients in both melanoma and NSCLC cancer populations (Figure 3B).

| Cancer type   | No.of trials | HR(95%CI) | I² | P   | No.of trials | HR(95%CI) | I² | P     |
|--------------|-------------|-----------|----|-----|-------------|-----------|----|-------|
| melanoma     | 6           | 0.53(0.46,0.60) | 5.00% | 0.385 | 2           | 0.60(0.46,0.79) | 0.00% | 0.383 |
| NSCLC        | 3           | 0.82(0.64,1.05) | 68.80% | 0.041 | 3           | 0.70(0.61.0.79) | 0.00% | 0.474 |
| Renal-cell Carcinoma | 1   | 0.88(0.75,1.03) | 0.00% | NA   | 1           | 0.73(0.58,0.92) | 0.00% | NA   |
| Drug type    |             |           |    |     |             |           |    |       |
| Nivolumab    | 7           | 0.63(0.48,0.83) | 83.90% | 0.000 | 4           | 0.69(0.62,0.78) | 0.00% | 0.405 |
| pembrolizumab| 2           | 0.58(0.49,0.68) | 0.00% | 0.918 | 1           | 0.63(0.47,0.83) | 0.00% | NA   |
| Atezolizumab | 1           | 0.94(0.72,1.23) | 0.00% | NA   | 1           | 0.73(0.53,0.99) | 0.00% | NA   |

NSCLC: Non-Small-Cell Lung Cancer; PFS: Progression-free survival; OS: Overall survival; HR: Hazard ratio; CI: Confidence interval; P: P-value of Q-test for heterogeneity test. NA: not available.
Figure 2: A. Forest plots of the pooled Hazard ratios (HRs) of Progressive-free survival (PFS) PFS in overall population. B. Forest plots of the pooled Hazard ratios (HRs) of Overall survival in overall population.
Objective response rate (ORR) and disease control rate (DCR) of nivolumab and pembrolizumab subgroups

Our studies involved two kinds of PD-1 inhibitors: nivolumab (7 articles) and pembrolizumab (2 articles). The ORR was significantly higher in the nivolumab groups than in the control groups (RR 3.09; 95% CI 2.14 to 4.45; \( P < 0.00001 \)) (Figure 5A). Although there was a similar trend in the pembrolizumab arms, the difference was not significant when compared with the control arms (RR 2.54; 95% CI 0.80 to 8.07; \( P = 0.11 \)) (Figure

Figure 3: Subgroup analysis of cancer types. A. Forest plots of the pooled Relative Risk (RR) of objective response rate (ORR); B. Forest plots of the pooled Relative Risk (RR) of disease control rate (DCR).
However, in regard to DCR, both nivolumab and pembrolizumab produced no significant difference from the control groups (Figure 5B).

Adverse events

In general, PD-1/PD-L1 inhibitors decreased AEs (1710/2303 for the PD1/PD-L1 inhibitor arms (74.3%) vs. 1787/2020 for the control arms (88.5%); \(P < 0.00001\)) (Figure 6A). This difference was more prominent in AEs with grade \(\geq 3\) (378/2161 of the PD-1/PD-L1 inhibitor arms (15.6%) vs. 518/2020 for the control arms (25.6%), \(P < 0.00001\)) (Figure 6B). The most common AEs (grade \(\geq 3\)) that emerged in the RCTs were fatigue (reported in 10 studies), nausea (9 studies), diarrhea (9 studies), and rash (6 studies). When compared with the control arms, PD-1 inhibitors had low toxicity and could also decrease the risk of anemia, asthenia, diarrhea, fatigue, nausea, neutropenia, leukopenia, and thrombocytopenia (Table 2).

Sensitivity analysis

Sensitivity analyses were carried out to evaluate the stability of the studies according to the effects of omitting each study. The sensitivity analysis results of PFS, ORR, SDR, and DCR showed that no individual study changed the pooled data overall, which suggests that our results are stable (Figure 7).

Publication bias analysis

Begg’s funnel plot and Egger’s test were applied to assess the publication bias of the studies (Figure 8). The Z-value of Begg’s test in the pooled analysis was 1.11 for PFS (\(P = 0.266\)), 0.73 for ORR (\(P = 0.466\)), 0.10 for SDR (\(P = 0.917\)), and 0.52 for DCR (\(P = 0.602\)). Egger’s test showed that the bias of the meta-analyses was -1.85 for PFS (\(P = 0.114\)), 0.63 for ORR (\(P = 0.546\)), -0.72 for SDR (\(P = 0.494\)), and 0.63 for DCR (\(P = 0.549\)). The statistical results show that the bias from publications does not have

### Table 3: Relative risks with 95% confidence intervals for common adverse events (Grade≥3).

| Adverse event          | No. of trials | Subjects          | RR [95% CI]       | \(P\)  | \(F\)%   | \(P^b\) |
|------------------------|---------------|-------------------|-------------------|------|--------|--------|
| Alopecia               | 2             | 309/300           | 0.32(0.03,3.10)   | 0.33 | 0      | 0.99   |
| Anaemia                | 5             | 1270/1067         | 0.18(0.10,0.34)   | <0.00001 | 0   | 0.95   |
| Arthralgia             | 3             | 724/529           | 0.31(0.06,1.75)   | 0.19 | 0      | 0.59   |
| Asthenia               | 5             | 1080/1029         | 0.28(0.09,0.88)   | 0.03 | 0      | 0.75   |
| Colitis                | 3             | 685/613           | 0.35(0.05,2.67)   | 0.31 | 88     | 0.0002 |
| Constipation           | 2             | 362/148           | 0.44(0.04,3.11)   | 0.5  | 12     | 0.29   |
| Decreased appetite     | 4             | 1137/1105         | 0.27(0.06,1.18)   | 0.08 | 0      | 0.68   |
| Diarrhoea              | 8             | 1755/1488         | 0.58(0.35,0.93)   | 0.03 | 0      | 0.56   |
| Fatigue                | 9             | 2161/1885         | 0.40(0.19,0.83)   | 0.01 | 41     | 0.1    |
| Nausea                 | 8             | 1955/1680         | 0.31(0.12,0.80)   | 0.02 | 0      | 0.92   |
| Neutropenia            | 3             | 596/568           | 0.02(0.00,0.09)   | <0.00001 | 0   | 0.42   |
| Pruritus               | 3             | 1496/989          | 0.44(0.10,1.83)   | 0.26 | 6      | 0.37   |
| Rash                   | 6             | 1428/1344         | 0.58(0.23,1.48)   | 0.26 | 0      | 0.42   |
| Dyspnea                | 3             | 813/754           | 2.02(0.51,8.00)   | 0.32 | 0.31   | 0.85   |
| Leukopenia             | 2             | 309/300           | 0.14(0.03,0.77)   | 0.02 | 0.3    | 0.58   |
| Maculopapular rash     | 2             | 272/217           | 3.18(0.37,27.22)  | 0.29 | 0.01   | 0.93   |
| Hypophysitis           | 2             | 372/302           | 0.35(0.08,1.49)   | 0.16 | 0.26   | 0.61   |
| Headache               | 2             | 407/357           | 0.96(0.11,8.61)   | 0.97 | 0.8    | 0.37   |
| Peripheral neuropathy  | 2             | 309/300           | 0.16(0.02,1.36)   | 0.09 | 0.02   | 0.88   |
| Pneumonitis            | 2             | 372/302           | 0.65(0.10,4.36)   | 0.66 | 0.33   | 0.57   |
| Pyrexia                | 3             | 538/486           | 0.79(0.13,4.73)   | 0.79 | 1.59   | 0.46   |
| Thrombocytopenia       | 2             | 384/376           | 0.07(0.01,0.54)   | 0.01 | 0.16   | 0.69   |

RR: Relative risk; CI: Confidence interval; \(P^b\): \(P\)-value of Q-test for heterogeneity test.
a significant influence on the results of our meta-analysis.

**DISCUSSION**

This meta-analysis included 10 RCTs and 5246 patients, and detailed data were extracted and calculated for PFS, OS, DCR, AEs, and other data. A comprehensive analysis was also done to evaluate the curative effect and safety of PD-1 inhibitors. PD-1 inhibitors presented a high curative effect on cancer patients. The PFS and OS of cancer patients treated with PD-1 inhibitors were improved significantly. In one of the trials [31], the median PFS of patients treated with PD-1 inhibitor was 11.5 months, while it was only 2.9 months for those treated without PD-1 inhibitor. It has been reported that a single dose of nivolumab could induce nearly a complete response in patients with cancer [32].

Our results also revealed that the ORR was 35% (715/2035) in PD-1 inhibitor treatment groups, while that in the control groups was only 11% (210/1812). The higher ORR also supported the longer PFS and OS in tumor patients treated with PD-1 inhibitors. Although the PD-1 inhibitors had a slight trend of increasing the disease control rate of cancer patients, it was not significant when compared with the control arms (1154/2035 for the PD-1 inhibitor arms (56.7%) vs. 857/1812 for the control arms (47.3%); \( P = 0.25 \)).

The DCR included complete response (CR), partial response (PR), and stable disease (SD). The main reason for the discrepancy between PFS/OS/ORR and DCR

| Study or Subgroup | Experimental Events | Control Events | Total | Weight | M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|---------------------|---------------|-------|--------|-------------------|-----------------------------|
| Borghaei H 2015   | 32                  | 180           | 212   | 179    | 4.8%              | 0.96 [0.62, 1.50]           |
| Brahmer J 2015    | 74                  | 292           | 172   | 290    | 17.9%             | 0.60 [0.47, 0.76]           |
| Larkin J 2015     | 35                  | 210           | 75    | 108    | 8.9%              | 0.39 [0.27, 0.57]           |
| Motzer R J 2015   | 37                  | 279           | 102   | 278    | 6.8%              | 0.80 [0.54, 1.20]           |
| Postow MA 2015    | 28                  | 120           | 38    | 47     | 3.4%              | 0.69 [0.41, 1.15]           |
| Ribas A 2015      | 39                  | 135           | 234   | 137    | 6.8%              | 0.84 [0.59, 1.20]           |
| Robert C 2014     | 41                  | 314           | 284   | 315    | 10.1%             | 0.60 [0.42, 0.85]           |
| Robert C 2015     | 12                  | 95            | 22    | 47     | 8.0%              | 0.14 [0.08, 0.25]           |
| Weber J S 2015    | 141                 | 410           | 553   | 411    | 33.2%             | 0.62 [0.53, 0.73]           |

Total (95% CI) = 2035 / 1812 = 100.0% 0.60 [0.55, 0.67]

Total events = 439 / 647

Heterogeneity: \( \chi^2 = 42.14 \), df = 8 (\( P < 0.00001 \)); \( \eta = 81\%

Test for overall effect: \( Z = 9.91 \) (\( P < 0.00001 \))

| Study or Subgroup | Experimental Events | Control Events | Total | Weight | M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|---------------------|---------------|-------|--------|-------------------|-----------------------------|
| Borghaei H 2015   | 64                  | 180           | 246   | 179    | 13.4%             | 0.75 [0.62, 0.91]           |
| Brahmer J 2015    | 129                 | 292           | 421   | 290    | 10.2%             | 1.51 [1.21, 1.88]           |
| Larkin J 2015     | 69                  | 210           | 288   | 108    | 16.0%             | 0.35 [0.29, 0.43]           |
| Motzer R J 2015   | 106                 | 279           | 213   | 278    | 16.4%             | 0.78 [0.64, 0.94]           |
| Postow MA 2015    | 41                  | 120           | 162   | 47     | 2.6%              | 1.07 [0.66, 1.74]           |
| Ribas A 2015      | 56                  | 135           | 205   | 48     | 5.7%              | 1.18 [0.87, 1.60]           |
| Robert C 2014     | 71                  | 314           | 385   | 154    | 18.5%             | 0.46 [0.37, 0.58]           |
| Robert C 2015     | 15                  | 95            | 29    | 47     | 3.5%              | 0.34 [0.19, 0.59]           |
| Weber J S 2015    | 143                 | 410           | 553   | 411    | 13.7%             | 1.26 [1.02, 1.54]           |

Total (95% CI) = 2035 / 1812 = 100.0% 0.80 [0.74, 0.87]

Total events = 714 / 786

Heterogeneity: \( \chi^2 = 154.66 \), df = 8 (\( P < 0.00001 \)); \( \eta = 95\%

Test for overall effect: \( Z = 5.50 \) (\( P < 0.00001 \))

**Figure 4:** A. Forest plots of the pooled Relative Risk (RR) of stable disease rate (SDR) and B. Forest plots of the pooled Relative Risk (RR) progressive disease rate (PDR).
### (A) ORR

| Study or Subgroup | Experimental Events | Total | Control Events | Total | Weight | M-H, Random, 95% CI | Risk Ratio |
|-------------------|---------------------|-------|----------------|-------|--------|---------------------|------------|
| **1.1 Nivolumab** |                     |       |                |       |        |                     |            |
| Borghaei 2015     | 94                  | 279   | 33             | 278   | 13.0%  | 2.84 [1.98, 4.07]   |            |
| Caroline 2014     | 56                  | 292   | 36             | 290   | 12.7%  | 1.54 [1.05, 2.27]   |            |
| Jeffrey 2015      | 38                  | 120   | 5              | 47    | 7.8%   | 2.96 [1.25, 7.10]   |            |
| Julie 2015        | 27                  | 135   | 12             | 137   | 10.0%  | 2.28 [1.12, 4.32]   |            |
| Larkin 2015       | 181                 | 314   | 60             | 315   | 14.0%  | 3.03 [2.36, 3.87]   |            |
| Michael 2015      | 56                  | 95    | 5              | 47    | 8.0%   | 5.54 [2.38, 12.90]  |            |
| Motzer 2015       | 141                 | 410   | 22             | 411   | 12.3%  | 6.42 [4.19, 9.86]   |            |
| **Subtotal (95% CI)** | **1645**            | **1525** | **77.9%**    |       |        | **3.09 [2.14, 4.45]** |            |

Total events: 593 / 173
Heterogeneity: Tau² = 0.17; Chi² = 26.91, df = 6 (P = 0.0002); I² = 78%
Test for overall effect: Z = 6.02 (P = 0.00001)

### (B) DCR

| Study or Subgroup | Experimental Events | Total | Control Events | Total | Weight | M-H, Fixed, 95% CI | Risk Ratio |
|-------------------|---------------------|-------|----------------|-------|--------|---------------------|------------|
| **3.2 Pembrolizumab** |                     |       |                |       |        |                     |            |
| Ribas A 2015      | 70                  | 180   | 41             | 179   | 4.5%   | 1.70 [1.23, 2.35]   |            |
| Robert.C 2014     | 119                 | 210   | 75             | 108   | 10.9%  | 0.82 [0.68, 0.97]   |            |
| **Subtotal (95% CI)** | **390**            | **287** | **15.5%**    |       |        | **1.07 [0.92, 1.26]** |            |

Total events: 189 / 116
Heterogeneity: Chi² = 17.42, df = 1 (P < 0.0001); I² = 94%
Test for overall effect: Z = 0.88 (P = 0.38)

### (C) Nivolumab

| Study or Subgroup | Experimental Events | Total | Control Events | Total | Weight | M-H, Fixed, 95% CI | Risk Ratio |
|-------------------|---------------------|-------|----------------|-------|--------|---------------------|------------|
| Borghaei 2015     | 130                 | 292   | 158            | 290   | 17.5%  | 0.82 [0.69, 0.96]   |            |
| Brahmer.J 2015    | 66                  | 135   | 59             | 137   | 6.5%   | 1.14 [0.88, 1.47]   |            |
| Larkin.J 2015     | 222                 | 314   | 129            | 315   | 14.2%  | 1.73 [1.49, 2.01]   |            |
| Motzer R.J 2015   | 282                 | 410   | 249            | 411   | 27.5%  | 1.14 [1.03, 1.26]   |            |
| Postow MA 2015    | 68                  | 95    | 46             | 47    | 6.8%   | 0.73 [0.64, 0.84]   |            |
| Robert.C 2015     | 131                 | 279   | 79             | 278   | 8.7%   | 1.66 [1.32, 2.07]   |            |
| Weber J.S 2015    | 66                  | 120   | 21             | 47    | 3.3%   | 1.23 [0.86, 1.76]   |            |
| **Subtotal (95% CI)** | **1645**            | **1525** | **84.5%**    |       |        | **1.19 [1.12, 1.27]** |            |

Total events: 965 / 741
Heterogeneity: Chi² = 104.04, df = 6 (P < 0.00001); I² = 94%
Test for overall effect: Z = 5.38 (P < 0.00001)

Total (95% CI): 2035 / 1812 / 100.0%
Risk Ratio: 1.18 [1.11, 1.25]

**Figure 5**: A. Forest plots of the pooled Relative Risk (RR) of objective response rate (ORR) in Subgroup analysis of nivolumab and pembrolizumab.; B. Forest plots of the pooled Relative Risk (RR) of disease control rate (DCR) in Subgroup analysis of nivolumab and pembrolizumab.
may be that so many patients reached the stable disease status in the control arms compared with the PD-1 arms that PD-1 inhibitors produced weak increases in the DCR. On the other hand, PD-1 inhibitors had a slight trend of decreasing the PDR compared with control arms (RR 0.76; 95% CI 0.53 to 1.09; \( P = 0.13 \)), although the difference was not significant. All of these results suggest that PD-1 inhibitors were better at improving the PFS, OS, and ORR of cancer patients, and they may have potential as powerful antitumor drug.

PD1/PD-L1 inhibitor drugs target immune checkpoints, and they may be very effective in the treatment of immune sensitive tumors. However, they may lack efficacy in some immune-insensitive cancers. The main cancers included in our research were melanoma (6 articles) and NSCLC (2 articles). Melanoma and NSCLC are immune-sensitive cancers and have the most abundant PD-L1 expression [33]. It has been reported that monoclonal antibodies against PD-1/PD-L1 interaction will prolong the OS in melanoma and NSCLC patients [34]. The FDA has approved the use of PD-1 inhibitors in the treatment of melanoma and NSCLC.

In this study, we evaluated the effect of PD-1 inhibitors on melanoma and NSCLC patients based on the ORR and DCR. Our results were consistent with previous reports, and PD-1 inhibitors showed a prominent effect in the treatment of melanoma and NSCLC. The ORR of patients treated with PD-1 increased significantly in the melanoma and NSCLC populations. PD-1 inhibitors are not limited to one tumor or tissue type [35]. In addition to

### Figure 6: A. Relative Risks (RR) of common adverse events of all grades. B. Relative Risks (RR) of adverse events of grade ≥ 3.
Figure 7: A. Sensitivity analysis of enrolled studies on progression-free survival (PFS). B. Sensitivity analysis of enrolled studies on objective response rate (ORR). C. Sensitivity analysis of enrolled studies on stable disease rate (SDR). D. Sensitivity analysis of enrolled studies on disease control rate (DCR).

Figure 8: A. Funnel plot of publication bias on progressive-free survival (PFS). B. Funnel plot of publication bias on objective response rate (ORR). C. Funnel plot of publication bias on stable disease rate (SDR). D. Funnel plot of publication bias on disease control rate (DCR).
melanoma and NSCLC, PD-1 inhibitors may also emerge as an effective antitumor strategy in various other common cancers, such as ovarian cancer, bladder cancer, and head and neck squamous cancer [30]. However, it seemed powerless to elevate the DCR of cancer patients in the present study. More effort is needed to clarify these results in the future.

It is well known that the immune system plays a vital role in antitumor activity. PD-1 is one of the important immune checkpoint receptors. In recent years, a series of drugs have been developed to target PD-1 checkpoint receptors, such as pembrolizumab, nivolumab, and pidilizumab [35]. Our study included two PD-1 inhibitors, nivolumab and pembrolizumab, which are monoclonal antibodies that bind to the PD-1 receptor and block its interaction with PD-L1 and PD-L2. This results in the release of the PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response [35, 36]. Both drugs were approved by the FDA for the treatment of cancers last year. We evaluated the antitumor effect of nivolumab and pembrolizumab, and the results showed that patients treated with these drugs had higher ORR (593/1645 (36%); 122/390 (31%)), which is in line with our expectations. However, the DCR of both nivolumab and pembrolizumab populations was not satisfactory. There was only one PD-L1 inhibitor in our study, and we had only enough data to compare anti-PD-1 and anti-PD-L1 immunotherapy.

The antitumor effect of PD-1 inhibitors is mainly due to the unrestrained T cell activation with immune checkpoint blockade, which may induce immune-related AEs. AEs like rash, fatigue, cough, diarrhea, constipation, and arthralgia were found in more than 20% of cancer patients receiving PD-1 inhibitors, but they were mainly grade 1 or 2 AEs and could be managed [36]. In this study, we pooled the total number of all grades of AEs, which showed that PD-1 inhibitors had an effect of decreasing AEs in all grade levels, especially AEs with grade ≥ 3. Traditional chemotherapeutics usually induce serious adverse events. However, our results revealed that PD-1 inhibitors have little toxicity and even have an effect of decreasing the risk of various AEs. In conclusion, PD-1 inhibitors are better for improving the PFS, OS, and ORR of cancer patients with little toxicity, but they are weak in increasing the DCR.

MATERIALS AND METHODS

Literature search and study selection

We carried out a comprehensive systematic retrieval for potential articles in the PubMed and EMBASE databases from inception to February 22th, 2017. The search terms used were “PD-1 inhibitors” or “PD-L1 inhibitors” or “Nivolumab” or “Pembrolizumab” or “Atezolizumab” or “BMS936559” or “MPDL3280A” or “Durvalumab” or “Avelumab” or “MED14736”, combined with “Cancer” or “Tumor” or “Carcinoma”. The search was limited to clinical trials without restrictions on publication language. For comprehensive retrieval of articles, we searched relevant meeting abstracts, clinical trials in the clinical trial registry (http://www.clinicaltrials.gov), and related review articles. To ensure the quality of eligible clinical trials, studies published with full text were included.

The following criteria were used for inclusion in the meta-analysis: randomized control trials (RCTs); the involvement of cancer patients; the use of PD-1/PD-L1 inhibitors alone or in combination with other agents for the treatment group along with placebo or other chemotherapeutic agents for the control group; at least one objective type of data reported, such as progression-free survival (PFS), overall survival (OS), objective response (including complete response and partial response), and adverse events. Studies were excluded in the following conditions: case reports; reviews; retrospective or prospective observational cohort studies; single-arm RCTs; and PD-1/PD-L1 inhibitors were used in both the experiment arms and control arms. When repeated studies were identified, the most elaborate and latest articles were included. Two investigators (Bao Z and Wang X) independently reviewed the articles for eligibility.

Data extraction

This systematic review was conducted according to the PRISMA guidelines. For each enrolled RCT, the following details were extracted and presented: the first author’s surname, journals, year of publication, number of participants, median age, sex (female vs. male), cancer type, clinical trial phase, treatment arm, median progression-free survival, BRAF status, and PD-L1 status. The following data were extracted for the systematic meta-analysis: progression-free survival (PFS) and overall survival (OS) (hazard ratio (HR) with 95% confidence interval (CI)), objective response (including complete response and partial response), stable disease and progressive disease, disease control rate (including complete response, partial response, and stable disease), and adverse events (AEs).

Statistical analysis

All pooled data were analyzed with Stata version 12.0 (StataCorp, College Station, Texas) and Review Manager (version 5.2, The Cochrane Collaboration, Oxford, UK). All statistical tests were two-sided, and P≤0.05 was considered statistically significant. The HR and 95% CIs were used to assess the OS and PFS between
the PD-1 inhibitor group and control group. Data on objective responses, stable disease, and adverse events were also pooled to calculate RR with 95% CIs. The degree of heterogeneity was measured by the $I^2$ statistic with $I^2 < 25\%$, 25-75%, and > 75% representing low, moderate, and high degrees of inconsistency, respectively.

We used a fixed-effect model if the heterogeneity was low in the analyses, and a random-effects model was applied otherwise. Subgroup analysis was also carried out according to the different tumor types and different PD-1 inhibitors. Sensitivity analysis was performed to observe the effect of a single study on the overall results. We used a Funnel plot and Egger’s regression asymmetry test to identify the potential publication bias of the studies [38].

**Author contributions**

Songmin Ying and Huahao Shen put forward the conception of this study and designed the paper. Xiaohui Wang, Zhengqiang Bao and Xiaoju Zhang extracted the data independently and wrote the full text together. Xiaohui Wang, Zhengqiang Bao and Fei Li analyzed the data together. Songmin Ying, Huahao Shen, Wen Li, Zhihua Chen, Chao Cao and Tianwen Lai contributed to various revisions of the article.

**ACKNOWLEDGMENTS**

This work was funded by the National 1000 Talents Program, the National Natural Science Foundation of China (81422031), Zhejiang Provincial Natural Science Foundation of China (LR14H160001), National Key Scientific and Technology Support Program: Collaborative innovation of Clinical Research for chronic obstructive pulmonary disease and lung cancer, no. 2013BAI09B09.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest in this work.

**REFERENCES**

1. Dietrich K, Theobald M. [Immunological tumor therapy]. Der Internist. 2015; 56:907-916; quiz 917.
2. Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends in pharmacological sciences. 2015; 36:587-595.
3. Kreamer KM. Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer. Journal of the advanced practitioner in oncology. 2014; 5:418.
4. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nature reviews Immunology. 2008; 8:467-477.
5. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H. Expression of Programmed Death 1 Ligands by Murine T Cells and APC. The Journal of Immunology. 2002; 169:5538-5545.
6. Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman GJ, Minato N, Honjo T. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunology letters. 2002; 84:57-62.
7. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current opinion in immunology. 2012; 24:207-212.
8. Sui X, Ma J, Han W, Wang X, Fang Y, Li D, Pan H, Zhang L. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/ PD-L1 antibodies in cancer patients. Oncotarget. 2015; 6:19393-19404. doi: 10.18632/oncotarget.5107.
9. Murphy A, Kelly RJ. Immunotherapy in upper GI malignancies. Current treatment options in oncology. 2015; 16:20.
10. Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN. Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunotherapy. 2015; 7:777-792.
11. Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Review of Anticancer Therapy. 2015; 15:981-993.
12. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New England Journal of Medicine. 2012; 366:2455-2465.
13. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine. 2012; 366:2443-2454.
14. Poole RM. Pembrolizumab: first global approval. Drugs. 2014; 74:1973-1981.
15. Mashima E, Inoue A, Sakuragi Y, Yamaguchi T, Sasaki N, Hara Y, Omoto D, Ohmori S, Haruyama S, Sawada Y, Yoshioka M, Nishio D, Nakamura M. Nivolumab in the treatment of malignant melanoma: review of the literature. Oncotargets and therapy. 2015; 8:2045-2051.
16. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carceny E, Ahn MJ, Felip E, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England journal of medicine. 2015; 372:2018-2028.
17. Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. British
journal of cancer. 2015; 112:1421-1427.
18. Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. Journal for immunotherapy of cancer. 2015; 3:36.
19. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. The Lancet Oncology. 2014; 15:69-77.
20. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon D, Sosman JA, McDermott DF, Powery JD, Gnepp D, Kohr H, Horn L, Lawrence DP, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515:563-567.
21. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlihauff M, Arrieta O, et al. Nivolumab versus Docetaxel in Advanced Non-Squamous Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015; 373:1627-1639.
22. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Puzanov I, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015; 373:123-135.
23. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowsk P, Ferrucci PF, Hill A, Wagstaff J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015; 373:23-34.
24. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Aaltonen A, Lewanski GP, Plimack ER, Castellano D, Choueiri TK, Gurney H, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre,open-label, phase 2 randomised controlled trial. The Lancet Oncology. 2016; 17:1837-1846.
25. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2015; 373:1803-1813.
26. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere J, Agarwala SS, Shaheen M, Ernstoff MS, Minov D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanona. The New England journal of medicine. 2015; 372:2006-2017.
27. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Crammer LD, Blank CU, O’Day SJ, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet Oncology. 2015; 16:908-918.
28. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hensberg MM, Lebbe C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. The New England journal of medicine. 2015; 372:320-330.
29. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlinos MS, McNeil C, Lotem M, Larkin J, Lorigan P, Nneys B, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2015; 372:2521-2532.
30. Weber J, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Nneys B, Hoeller C, Khushalani N, Miller WH, Lao CD, Linette GP, Thomas L, Lorigan P, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 2015; 16:375-384.
31. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015; 373:1270-1271.
32. Davar D, Socinski MA, Dacie S, Burns TF. Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. Experimental hematology & oncology. 2015; 4:34.
33. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clinical cancer research. 2014; 20:5064-5074.
34. Wieder T, Brenner E, Braumuller H, Rocken M. Immunotherapy of melanoma: efficacy and mode of action. Journal of the German Society of Dermatology: JDDG. 2016; 14:28-36.
35. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer. 2012; 12:252-264.
36. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Translational lung cancer research. 2015; 4:560-575.
37. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ: British Medical Journal. 2003; 327:557.
38. Eger M, Smith GD, Schneider M, Minder C. Bias in meta-analyses detected by a simple, graphical test. Bmj. 1997; 315:629-634.